MeiraGTx secures $135 million royalty deal with Oberland Capital

MeiraGTx announced a royalty financing agreement with Oberland Capital. The deal provides the gene-therapy company with an initial $135 million, including a $10 million equity investment from Oberland. The funding is intended to support MeiraGTx’s ongoing development of its gene-therapy pipeline.

The agreement structures future royalty payments from MeiraGTx’s product sales to Oberland Capital, giving the investor a share of commercial revenues. This arrangement gives MeiraGTx immediate capital while aligning long-term interests with its partner.

The transaction highlights continued investor interest in gene-therapy companies and adds to MeiraGTx’s financial resources as it advances its programs toward regulatory milestones.